がん診断用リキッドバイオプシーの世界市場レポート 2025年

がん診断用リキッドバイオプシー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR15.7％で193億2,000万米ドルに成長します。予測期間における成長は、ルーチンがん診断におけるリキッドバイオプシーの統合、早期がん発見のためのリキッドバイオプシーの採用、がん検診プログラムの拡大、がん医療における個別化医療への注目の高まり、リキッドバイオプシー研究への資金提供の増加などに起因すると考えられます。予測期間における主な動向には、マルチオミクスによるリキッドバイオプシーアプローチの出現、リキッドバイオプシー分析における人工知能の統合、がん領域以外へのリキッドバイオプシー応用の拡大、血液ベースのがんバイオマーカーの開発、特定のがん種に対するリキッドバイオプシーアッセイのカスタマイズなどがあります。

がんの罹患率の増加は、がん診断用リキッドバイオプシー市場の今後の成長を牽引すると予想されます。がんは、異常な細胞が制御不能に増殖し、典型的な境界を突破して他の臓器に転移したり、隣接する組織に侵入したりすることにより、体内のほとんどすべての臓器や組織に発生する可能性のある広範な疾患を包含します。このようながん患者の急増は、がんや腫瘍再発の早期発見、患者のリスク評価、治療モニタリングなどの診断方法に対する需要を高めています。リキッドバイオプシーは、原発巣や転移巣から放出される腫瘍細胞やその産物を捕捉することで重要な役割を果たし、腫瘍の進化、治療標的、治療抵抗性のメカニズムに関する包括的かつリアルタイムの洞察を提供します。例えば、米国の政府機関である国立がん研究所は、2024年5月、米国におけるがん生存者数を約1,810万人と報告し、この数は2032年までに2,250万人に増加すると予測しています。さらに、2040年までに新たに発生するがん患者は年間2,990万人に達し、がんに関連した死亡者数は1,530万人になると予測されています。このように、がんの有病率の増加ががん診断用リキッドバイオプシー市場の成長を後押ししています。

個別化医療に対する需要の高まりが、将来のがん診断用リキッド生検市場の成長を促進すると予想されます。個別化医療は、患者の遺伝、環境、ライフスタイルの個人差を考慮したヘルスケアへの画期的なアプローチです。リキッドバイオプシーは、がんに関連する特定の遺伝子変異やバイオマーカーを同定する上で重要な役割を果たし、それによってオーダーメイドで的を絞った治療戦略の開発が可能になります。例えば、米国を拠点とする専門家会員組織である個別化医療連合（Personalized Medicine Coalition）は、2022年に12の個別化新薬の承認が新たに承認された治療法全体の約34％を占め、以前より大幅に増加したと報告しています。その結果、個別化医療に対する需要の高まりが、がん診断用リキッドバイオプシー市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん診断用リキッドバイオプシーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のがん診断用リキッドバイオプシー市場：成長率分析
• 世界のがん診断用リキッドバイオプシー市場の実績：規模と成長, 2019-2024
• 世界のがん診断用リキッドバイオプシー市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん診断用リキッドバイオプシー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん診断用リキッドバイオプシー市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製品
• サービス
• 世界のがん診断用リキッドバイオプシー市場サンプル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血
• 尿
• 唾液
• 世界のがん診断用リキッドバイオプシー市場がん、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺がん
• 乳がん
• 大腸がん
• その他のがん
• 世界のがん診断用リキッドバイオプシー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• その他のエンドユーザー
• 世界のがん診断用リキッドバイオプシー市場、製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 循環腫瘍細胞（CTC）検出キット
• 循環腫瘍DNA（ctDNA）検出キット
• エクソソーム分離キット
• サンプル収集装置
• 世界のがん診断用リキッドバイオプシー市場、サービスの種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• テストサービス
• 分析サービス
• バイオインフォマティクスサービス

第7章 地域別・国別分析

• 世界のがん診断用リキッドバイオプシー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん診断用リキッドバイオプシー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん診断用リキッドバイオプシー市場：競合情勢
• がん診断用リキッドバイオプシー市場：企業プロファイル
  • F. Hoffman La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • The Menarini Group Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Rad Laboratories Inc.
• QIAGEN Inc.
• Exact Sciences Corporation
• Bio-Techne Corporation
• ArcherDX Inc.
• Neogenomics Laboratories Inc.
• Guardant Health Inc.
• Myriad Genetics Inc.
• Foundation Medicine Inc.
• Amoy Diagnostics Co. Ltd.
• Biocartis Group NV
• Biodesix Inc.
• MDx Health Inc.
• Sysmex Inostics Inc.
• Biocept Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん診断用リキッドバイオプシー市場2029：新たな機会を提供する国
• がん診断用リキッドバイオプシー市場2029：新たな機会を提供するセグメント
• がん診断用リキッドバイオプシー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Liquid biopsy for cancer diagnostics offers a less invasive alternative to traditional tissue biopsies, involving the assessment of genetic material or biomarkers found in a patient's blood or other bodily fluids to detect and monitor the presence of cancer. This approach is commonly utilized for screening and identifying non-small cell lung cancer (NSCLC) and is also employed as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

The main categories within liquid biopsy for cancer diagnostics encompass products and services. Products refer to procedures, methods, or tools designed or utilized for identifying illnesses or diseases in humans or other vertebrate animals. Various types of samples, such as blood, urine, and saliva, are utilized in this diagnostic approach. Liquid biopsy for cancer diagnostics is applicable to various types of cancer, including lung cancer, breast cancer, colon cancer, and others. The end-users for these diagnostics include hospitals, diagnostic centers, and other healthcare institutions.

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liquid biopsy for cancer diagnostics market statistics, including liquid biopsy for cancer diagnostics industry global market size, regional shares, competitors with a liquid biopsy for cancer diagnostics market share, detailed liquid biopsy for cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. This liquid biopsy for cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $9.23 billion in 2024 to $10.78 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to advancements in genomic research, growing awareness of liquid biopsy benefits, increased prevalence of cancer, rise in demand for non-invasive cancer testing, expansion of precision medicine initiatives

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $19.32 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to integration of liquid biopsy in routine cancer diagnostics, adoption of liquid biopsy for early cancer detection, expansion of cancer screening programs, growing focus on personalized medicine in oncology, increased funding for liquid biopsy research. Major trends in the forecast period include emergence of multi-omics liquid biopsy approaches, integration of artificial intelligence in liquid biopsy analysis, expansion of liquid biopsy applications beyond oncology, development of blood-based biomarkers for cancer, customization of liquid biopsy assays for specific cancer types.

The increasing incidence of cancer is anticipated to drive the growth of the liquid biopsy market for cancer diagnostics in the future. Cancer encompasses a wide range of diseases that can arise in almost any organ or tissue in the body when abnormal cells grow uncontrollably, breach their typical boundaries, and either spread to other organs or invade adjacent tissues. This surge in cancer cases heightens the demand for diagnostic methods, such as early detection of cancer or tumor recurrence, patient risk assessment, and therapy monitoring. Liquid biopsy plays a crucial role by capturing tumor cells or their products released from primary or metastatic sites, offering comprehensive and real-time insights into tumor evolution, therapeutic targets, and mechanisms of treatment resistance. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, reported approximately 18.1 million cancer survivors in the United States, with projections suggesting this number will rise to 22.5 million by 2032. Furthermore, by 2040, the annual incidence of new cancer cases is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Thus, the increasing prevalence of cancer is propelling the growth of the liquid biopsy market for cancer diagnostics.

The rising demand for personalized medicine is expected to drive the growth of the liquid biopsy market for cancer diagnostics in the future. Personalized medicine represents a groundbreaking approach to healthcare that takes into account individual differences in patients' genetics, environments, and lifestyles. Liquid biopsy plays a crucial role in identifying specific genetic mutations and biomarkers linked to cancer, thereby enabling the development of tailored and targeted treatment strategies. For example, the Personalized Medicine Coalition, a U.S.-based professional membership organization, reported that in 2022, the approval of 12 new personalized medicines accounted for approximately 34% of all newly approved therapies, reflecting a significant increase from previous years. Consequently, the growing demand for personalized medicine is fueling the expansion of the liquid biopsy market for cancer diagnostics.

A prominent trend gaining traction is the focus on product innovations by major companies. These companies are strategically investing in the development of cutting-edge products to bolster their market position. An exemplar of this trend is BostonGene, a US-based biomedical software company, which introduced new liquid biopsy solutions in June 2023. These solutions aim to identify clinically relevant gene alterations, expanding the test portfolio and accelerating the development of novel assays, analytical tools, and pipelines. The innovative approach involves leveraging artificial intelligence-driven molecular and immunological profiling methodologies to analyze tumors, microenvironments, and host immunity. Notably, these solutions support immunotherapy treatment, provide insights into a patient's immune-related disorders, and enable the monitoring of disease progression and response to treatment.

Major players in the liquid biopsy for cancer diagnostics market are directing their efforts toward the development of advanced liquid biopsy assays. These assays, characterized by sophistication and refinement, analyze various components within liquid biological samples, such as blood or other bodily fluids. The objective is to detect and characterize specific biomarkers associated with cancer or other diseases. Illumina Inc., a global leader in DNA sequencing, exemplifies this focus on innovation. In November 2023, the company announced the launch of the 'TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)' research assay. This assay facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. Designed to streamline integration for users, the TSO 500 ctDNA v2 assay enhances the depth of insights available for cancer research.

In January 2022, when Exact Sciences Corp., a US-based molecular diagnostics company, acquired Thrive Earlier Detection Corp. for $2.15 billion. This strategic acquisition positions Exact Sciences Corp. to access clinical and regulatory teams, scale laboratory and IT capabilities, and advance blood-based, multi-cancer screening, aligning with evolving norms in cancer treatment. Thrive Earlier Detection Corp., known for its expertise in producing liquid biopsy tests, focuses on the early detection of multiple cancers.

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also include sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liquid Biopsy For Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liquid biopsy for cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liquid biopsy for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liquid biopsy for cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Product; Services
• 2) By Sample: Blood; Urine; Saliva
• 3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
• 4) By End-User: Hospitals; Diagnostic Centers; Other End-Users
• Subsegments:
• 1) By Product: Circulating Tumor Cells (CTCs) Detection Kits; Circulating Tumor DNA (ctDNA) Detection Kits; Exosome Isolation Kits; Sample Collection Devices
• 2) By Services: Testing Services; Analytical Services; Bioinformatics Services
• Companies Mentioned: F. Hoffman La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; The Menarini Group
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liquid Biopsy For Cancer Diagnostics Market Characteristics

3. Liquid Biopsy For Cancer Diagnostics Market Trends And Strategies

4. Liquid Biopsy For Cancer Diagnostics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Liquid Biopsy For Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liquid Biopsy For Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liquid Biopsy For Cancer Diagnostics Market Growth Rate Analysis
• 5.4. Global Liquid Biopsy For Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liquid Biopsy For Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liquid Biopsy For Cancer Diagnostics Total Addressable Market (TAM)

6. Liquid Biopsy For Cancer Diagnostics Market Segmentation

• 6.1. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Product
• Services
• 6.2. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood
• Urine
• Salive
• 6.3. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colon Cancer
• Other Cancers
• 6.4. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Other End-Users
• 6.5. Global Liquid Biopsy For Cancer Diagnostics Market, Sub-Segmentation Of Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Circulating Tumor Cells (CTCs) Detection Kits
• Circulating Tumor DNA (ctDNA) Detection Kits
• Exosome Isolation Kits
• Sample Collection Devices
• 6.6. Global Liquid Biopsy For Cancer Diagnostics Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Testing Services
• Analytical Services
• Bioinformatics Services

7. Liquid Biopsy For Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market

• 8.1. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liquid Biopsy For Cancer Diagnostics Market

• 9.1. China Liquid Biopsy For Cancer Diagnostics Market Overview
• 9.2. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liquid Biopsy For Cancer Diagnostics Market

• 10.1. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liquid Biopsy For Cancer Diagnostics Market

• 11.1. Japan Liquid Biopsy For Cancer Diagnostics Market Overview
• 11.2. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liquid Biopsy For Cancer Diagnostics Market

• 12.1. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liquid Biopsy For Cancer Diagnostics Market

• 13.1. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liquid Biopsy For Cancer Diagnostics Market

• 14.1. South Korea Liquid Biopsy For Cancer Diagnostics Market Overview
• 14.2. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liquid Biopsy For Cancer Diagnostics Market

• 15.1. Western Europe Liquid Biopsy For Cancer Diagnostics Market Overview
• 15.2. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liquid Biopsy For Cancer Diagnostics Market

• 16.1. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liquid Biopsy For Cancer Diagnostics Market

• 17.1. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liquid Biopsy For Cancer Diagnostics Market

• 18.1. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liquid Biopsy For Cancer Diagnostics Market

• 19.1. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liquid Biopsy For Cancer Diagnostics Market

• 20.1. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market

• 21.1. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liquid Biopsy For Cancer Diagnostics Market

• 22.1. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liquid Biopsy For Cancer Diagnostics Market

• 23.1. North America Liquid Biopsy For Cancer Diagnostics Market Overview
• 23.2. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liquid Biopsy For Cancer Diagnostics Market

• 24.1. USA Liquid Biopsy For Cancer Diagnostics Market Overview
• 24.2. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liquid Biopsy For Cancer Diagnostics Market

• 25.1. Canada Liquid Biopsy For Cancer Diagnostics Market Overview
• 25.2. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liquid Biopsy For Cancer Diagnostics Market

• 26.1. South America Liquid Biopsy For Cancer Diagnostics Market Overview
• 26.2. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liquid Biopsy For Cancer Diagnostics Market

• 27.1. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liquid Biopsy For Cancer Diagnostics Market

• 28.1. Middle East Liquid Biopsy For Cancer Diagnostics Market Overview
• 28.2. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liquid Biopsy For Cancer Diagnostics Market

• 29.1. Africa Liquid Biopsy For Cancer Diagnostics Market Overview
• 29.2. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape
• 30.2. Liquid Biopsy For Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffman La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Menarini Group Overview, Products and Services, Strategy and Financial Analysis

31. Liquid Biopsy For Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Bio-Rad Laboratories Inc.
• 31.2. QIAGEN Inc.
• 31.3. Exact Sciences Corporation
• 31.4. Bio-Techne Corporation
• 31.5. ArcherDX Inc.
• 31.6. Neogenomics Laboratories Inc.
• 31.7. Guardant Health Inc.
• 31.8. Myriad Genetics Inc.
• 31.9. Foundation Medicine Inc.
• 31.10. Amoy Diagnostics Co. Ltd.
• 31.11. Biocartis Group NV
• 31.12. Biodesix Inc.
• 31.13. MDx Health Inc.
• 31.14. Sysmex Inostics Inc.
• 31.15. Biocept Inc.

32. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liquid Biopsy For Cancer Diagnostics Market

34. Recent Developments In The Liquid Biopsy For Cancer Diagnostics Market

35. Liquid Biopsy For Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liquid Biopsy For Cancer Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer